Related references
Note: Only part of the references are listed.Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation
Andrea Tendas et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study
Atsushi Isoda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy
Jorn Herrstedt et al.
SUPPORTIVE CARE IN CANCER (2017)
Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study
Steven Trifilio et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant
Stephen Michael Clark et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F. Roila et al.
ANNALS OF ONCOLOGY (2016)
Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study
Laurence Fardet et al.
PLOS MEDICINE (2016)
Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need
Andrea Tendas et al.
SUPPORTIVE CARE IN CANCER (2015)
Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial
Thomas Schmitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study
Thomas Bechtel et al.
SUPPORTIVE CARE IN CANCER (2014)
Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study
Delva Deauna-Limayo et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
Effectiveness and Safety of Antiemetic Aprepitant in Japanese Patients Receiving High-Dose Chemotherapy Prior to Autologous Hematopoietic Stem Cell Transplantation
Mayako Uchida et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2013)
A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function
Muneer H. Abidi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide
Michael A. Cox et al.
CELL AND TISSUE BANKING (2012)
Electrocardiographic findings of palonosetron in cancer patients
Guzin Gonullu et al.
SUPPORTIVE CARE IN CANCER (2012)
Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant
Andrea Tendas et al.
SUPPORTIVE CARE IN CANCER (2012)
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation
S. A. Giralt et al.
ANNALS OF ONCOLOGY (2011)
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination
K. Jordan et al.
BONE MARROW TRANSPLANTATION (2011)
Aprepitant: drug-drug interactions in perspective
M. S. Aapro et al.
ANNALS OF ONCOLOGY (2010)
Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT
M. Musso et al.
BONE MARROW TRANSPLANTATION (2010)
Mechanisms of glucocorticoid-induced myopathy
O. Schakman et al.
JOURNAL OF ENDOCRINOLOGY (2008)
Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis
S. M. Grunberg
ANNALS OF ONCOLOGY (2007)
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists
RM Navari et al.
ANNALS OF PHARMACOTHERAPY (2003)
Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects
M Feuring et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
SP Chawla et al.
CANCER (2003)
5-HT3-receptor antagonists for the treatment of nausea and vomiting: A reappraisal of their side-effect profile
S Goodin et al.
ONCOLOGIST (2002)
Share Paper
